Role of Ivermectin in Management of Covid-19; A Systematic Review and Meta-Analysis | ||
| Ain-Shams Journal of Anesthesiology | ||
| Volume 17, Issue 1, January 2025, Pages 1-8 PDF (627.53 K) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/asja.2024.278348.1099 | ||
| Authors | ||
| Bahaa Eldin Hassan Helal* ; Hanaa Elgendy; Amal Rabie; Heba Ahmed; Wael Omran | ||
| Department of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Egypt. | ||
| Abstract | ||
| Background: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. Results We found in our systematic review that compared with SOC or placebo, IVM did not reduce primary outcomes (all-cause mortality rate and LOS) or secondary outcomes (SARS-CoV-2 clearance in respiratory samples, mild and severe adverse events) in RCTs of patients with mostly mild COVID-19 disease. The QoE was low or very low for all outcomes. Results of subgroup analyses by severity of COVID-19 disease or RoB were mostly consistent with those of the main analyses, except for a significant effect on all-cause mortality rate in 2 RCTs with significant RoB and very low QoE. Conclusions Compared with SOC or placebo, Ivermectin did not reduce all-cause mortality rate, LOS, respiratory viral clearance, mild adverse effects, or severe adverse effects in RCTs of patients with mild to moderate COVID-19. We did not find data about Ivermectin effects on clinical improvement or the need for mechanical ventilation. Additional ongoing RCTs should be completed to update our analyses. In the meanwhile, Ivermectin is not a viable option for treating patients with COVID-19 and should be used only within clinical trials. | ||
| Keywords | ||
| Ivermectin; COVID 19; SARS COV 2; IVM | ||
|
Statistics Article View: 5 PDF Download: 7 |
||
